162 related articles for article (PubMed ID: 21546493)
1. The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.
van Dorp S; Resemann H; te Boome L; Pietersma F; van Baarle D; Gmelig-Meyling F; de Weger R; Petersen E; Minnema M; Lokhorst H; Ebeling S; Beijn SJ; Knol EF; van Dijk M; Meijer E; Kuball J
Haematologica; 2011 Sep; 96(9):1380-4. PubMed ID: 21546493
[TBL] [Abstract][Full Text] [Related]
2. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.
Kim SJ; Lee JW; Jung CW; Min CK; Cho B; Shin HJ; Chung JS; Kim H; Lee WS; Joo YD; Yang DH; Kook H; Kang HJ; Ahn HS; Yoon SS; Sohn SK; Min YH; Min WS; Park HS; Won JH
Haematologica; 2010 Nov; 95(11):1935-42. PubMed ID: 20663943
[TBL] [Abstract][Full Text] [Related]
3. B cells in chronic graft-versus-host disease.
Sarantopoulos S; Blazar BR; Cutler C; Ritz J
Biol Blood Marrow Transplant; 2015 Jan; 21(1):16-23. PubMed ID: 25452031
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.
Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Borjas-Almaguer OD; González-Llano O; Jaime-Pérez JC; Solano-Genesta M; Gómez-Guijosa M; Mancias-Guerra C; Tarin L; Gómez-Almaguer D
Haematologica; 2012 May; 97(5):717-22. PubMed ID: 22133770
[TBL] [Abstract][Full Text] [Related]
7. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
Sarantopoulos S; Stevenson KE; Kim HT; Washel WS; Bhuiya NS; Cutler CS; Alyea EP; Ho VT; Soiffer RJ; Antin JH; Ritz J
Blood; 2011 Feb; 117(7):2275-83. PubMed ID: 21097674
[TBL] [Abstract][Full Text] [Related]
8. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.
Alousi AM; Uberti J; Ratanatharathorn V
Leuk Lymphoma; 2010 Mar; 51(3):376-89. PubMed ID: 20141428
[TBL] [Abstract][Full Text] [Related]
9. B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy.
Kim SJ; Won JH
Leuk Lymphoma; 2012 Jan; 53(1):19-25. PubMed ID: 21740304
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for prevention and treatment of graft-versus-host disease.
Kharfan-Dabaja MA; Cutler CS
Int J Hematol; 2011 May; 93(5):578-585. PubMed ID: 21547615
[TBL] [Abstract][Full Text] [Related]
11. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.
McIver Z; Stephens N; Grim A; Barrett AJ
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1549-56. PubMed ID: 20580848
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease.
Teshima T; Nagafuji K; Henzan H; Miyamura K; Takase K; Hidaka M; Miyamoto T; Takenaka K; Akashi K; Harada M
Int J Hematol; 2009 Sep; 90(2):253-260. PubMed ID: 19543951
[TBL] [Abstract][Full Text] [Related]
13. B-cell involvement in chronic graft-versus-host disease.
Kapur R; Ebeling S; Hagenbeek A
Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
[TBL] [Abstract][Full Text] [Related]
15. Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease.
Khandelwal P; Lane A; Chaturvedi V; Owsley E; Davies SM; Marmer D; Filipovich AH; Jordan MB; Marsh RA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1215-22. PubMed ID: 25881755
[TBL] [Abstract][Full Text] [Related]
16. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
Glass B; Hasenkamp J; Wulf G; Dreger P; Pfreundschuh M; Gramatzki M; Silling G; Wilhelm C; Zeis M; Görlitz A; Pfeiffer S; Hilgers R; Truemper L; Schmitz N;
Lancet Oncol; 2014 Jun; 15(7):757-66. PubMed ID: 24827808
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.
Kuzmina Z; Gounden V; Curtis L; Avila D; Rnp TT; Baruffaldi J; Cowen EW; Naik HB; Hasni SA; Mays JW; Mitchell S; Baird K; Steinberg SM; Pavletic SZ
Am J Hematol; 2015 Feb; 90(2):114-9. PubMed ID: 25363867
[TBL] [Abstract][Full Text] [Related]
18. Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten.
Van Hoef ME
Haematologica; 2013 Apr; 98(4):e40-1. PubMed ID: 23543154
[No Abstract] [Full Text] [Related]
19. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
Arai S; Sahaf B; Narasimhan B; Chen GL; Jones CD; Lowsky R; Shizuru JA; Johnston LJ; Laport GG; Weng WK; Benjamin JE; Schaenman J; Brown J; Ramirez J; Zehnder JL; Negrin RS; Miklos DB
Blood; 2012 Jun; 119(25):6145-54. PubMed ID: 22563089
[TBL] [Abstract][Full Text] [Related]
20. B-cell-directed therapy for chronic graft-versus-host disease.
Jacobson CA; Ritz J
Haematologica; 2010 Nov; 95(11):1811-3. PubMed ID: 21037328
[No Abstract] [Full Text] [Related]
[Next] [New Search]
